Nov 9 (Reuters) - Recce Pharmaceuticals Ltd (RCE) :
- RECCE PHARMACEUTICALS COMPLETES DOSING FIRST SUBJECTS AT 15-MINUTE INFUSION RATE IN A PHASE I/II TRIAL OF RECCE® 327 FOR URINARY TRACT INFECTIONS AND UROSEPSIS
- RECCE PHARMACEUTICALS LTD: PHASE I/II STUDY IS TRACKING TO MEET PRIMARY ENDPOINTS
News: RCE Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.025(5.62%) |
Mkt cap ! $121.4M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.0¢ | 41.5¢ | $45.92K | 107.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 120 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 15.59pm 28/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |